SpyGlass Pharma, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing share count, product development status, and an acknowledged material weakness in internal controls.
Key Highlights
- Share count: As of November 2, 2026, SpyGlass Pharma had 33,461,450 shares of common stock, par value $0.00001 per share, outstanding.
- Lead product candidate: The filing identifies the Bimatoprost Drug Pad-IOL System (the BIM-IOL System) as the company's lead product candidate.
- Second product candidate: The company also disclosed its second product candidate, the Bimatoprost Drug-Ring System (BIM-DRS), according to the filing.
- Material weakness: The filing references efforts directed at "remediating the material weakness in our internal control over financial reporting."
- Company classification: SpyGlass Pharma is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under applicable SEC definitions.
- License agreement: The filing discloses the company's reliance on a license agreement with the Regents of the University of Colorado, including development and commercial milestones.
SpyGlass Pharma's Quarterly Disclosure: Product Pipeline and Internal Control Remediation
SpyGlass Pharma, Inc. (NASDAQ:SGP), a Delaware-incorporated pharmaceutical company headquartered at 15326 Alton Parkway, Irvine, California, submitted its Form 10-Q for the quarter ended September 30, 2026. The filing reported 33,461,450 shares of common stock outstanding as of November 2, 2026, at a par value of $0.00001 per share. The company holds Commission file number 001-43105.
According to the filing, SpyGlass Pharma is focused on two product candidates. The lead candidate is the Bimatoprost Drug Pad-IOL System, referred to as the BIM-IOL System, and the second candidate is the Bimatoprost Drug-Ring System, referred to as BIM-DRS. The company disclosed its ongoing reliance on a license agreement with the Regents of the University of Colorado, noting that it must meet development and commercial milestones to maintain its intellectual property rights under that agreement. The filing also indicates continued reliance on third parties, including clinical sites, to conduct clinical trials and manufacture product candidates.
The filing expressly lists "remediating the material weakness in our internal control over financial reporting" among the subjects addressed by forward-looking statements, indicating the issue is an active area of management focus. SpyGlass Pharma is classified as an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act, according to the filing. The company also confirmed it is not a shell company.
What Was Disclosed
SpyGlass Pharma filed a quarterly report covering the period ended September 30, 2026, disclosing 33,461,450 shares outstanding, two bimatoprost-based product candidates in development, a University of Colorado license dependency, and an ongoing effort to remediate a material weakness in internal controls.




Please wait processing your request...